Tuberous sclerosis (TSC) is a rare genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin.
What is Tuberous Sclerosis?
Tuberous sclerosis is a genetic disease that causes benign tumors to develop in different parts of the body.
Researchers have solved a medical mystery in a poorly understood disease by uncovering which cells cause tumors in patients with tuberous sclerosis complex (TSC).
Infantile spasm (IS) is a severe epileptic syndrome of infancy and accounts for 50% of all epilepsy cases that occur in babies during the first year of life.
People with neurofibromatosis type 1 (NF1) develop tumors on nerves throughout their bodies. These tumors are usually benign -; meaning they don't spread to other parts of the body and are not considered life-threatening -; but they can still cause serious medical problems such as blindness, especially when they form in the brain and nerves.
Timing is key when treating developmental disorders. Blocking an overactive signaling pathway during the first five weeks of life prevents autism symptoms from ever developing in mice, according to new research published in JNeurosci.
There's not much good that can be said about asthma, a breathing disease in which the airways become narrowed and inflamed.
Children with infantile spasms, a rare form of epileptic seizures, should be treated with one of three recommended therapies and the use of non-standard therapies should be strongly discouraged, according to a study of their effectiveness by a Weill Cornell Medicine and NewYork-Presbyterian investigator and collaborating colleagues in the Pediatric Epilepsy Research Consortium. Early treatment with an effective therapy is important for improving neurodevelopmental outcomes and, for some children, can result in permanent remission of epilepsy.
Artisanal (non-pharmaceutical) cannabidiol (CBD) products have become popular in recent years for their apparent therapeutic effects. CBD — a naturally occurring compound of the cannabis plant legally derived from hemp — is used widely as a naturopathic remedy for a number of health conditions, including epilepsy and seizure disorders.
Tuberous Sclerosis Complex (TSC) affects between one and two of every 10,000 new-born babies. This genetic disease leads to the formation of benign tumors which can massively impair the proper functioning of vital organs such as the kidneys, the liver and the brain.
A team of researchers led by UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital (GOSH) has found that metformin - a drug commonly used to treat Type 2 diabetes - can successfully reduce symptoms associated with tuberous sclerosis complex (TSC), including reduction in the frequency of seizures and the size of brain tumors.
The U.S. Food and Drug Administration has issued warning letters to two companies for selling products labeled as containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Tuberous sclerosis complex (TSC) afflicts as many as two million people around the world, affecting multiple organs, including lungs, brain, skin and kidneys. In about 80 percent of cases, it causes cysts and benign tumors to form in the kidney, eventually resulting in kidney failure.
G3BP proteins inhibit the metabolic driver MTOR - a signaling protein that plays a central role in tumor diseases and developmental disorders of the brain. This is reported in this week´s issue of the renowned journal Cell.
Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders.
Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options.
Today, the U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.
A team led by UT Southwestern researchers has identified brain circuitry that plays a key role in the dysfunctional social, repetitive, and inflexible behavioral differences that characterize autism spectrum disorders (ASD).
College of Science associate professor and researcher David Feliciano has received a $667,000 grant from the Department of Defense to explore the cellular underpinnings of Tuberous Sclerosis Complex (TSC), a developmental disorder characterized by the growth of benign tumors throughout the body, most notably in the brain.
Tuberous sclerosis complex (TSC) is a neurological disorder causing non-cancerous tumors, called cortical tubers, to grow throughout the brain and body, as well as other conditions like epilepsy and autism.
The University of Maryland School of Medicine, University of Maryland Medical Center, and the Tuberous Sclerosis Alliance have joined together to launch first-of-a-kind centers in Maryland to treat adults with neurodevelopmental disabilities, such as autism.